Israeli biotechnology company Kadimastem reports that it has signed a collaboration agreement with Merck to carry out drug screening in the neurodegenerative diseases space for multiple sclerosis , and potential other neurodegenerative diseases.
http://ift.tt/1oepQh5
http://ift.tt/1oepQh5
No comments:
Post a Comment